You are here: Trials Coordinating Centre | BRAIN trial

Bradykinin B2 Receptor Antagonist (Anatibant) in Neurotrauma
A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury
ISRCTN23625128
The trial protocol summary can be accessed HERE
The BRAIN trial was subject to a legal dispute. Public court documents are listed below.

REDACTED COURT TRANSCRIPTS

Some sections of the hearing pertaining to unblinded data were heard in closed court. The transcripts of those sections have been removed from these documents.

PUBLICATION

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Haleema Shakur, Peter Andrews, Toomas Asser, Laura Balica, Cristian Boeriu, Juan Diego Ciro Quintero, Yashbir Dewan, Patrick Druwe, Olivia Fletcher, Chris Frost, Bennie Hartzenberg, Jorge Mejia Mantilla, Francisco Murillo-Cabezas, Jan Pachl, Ramalingam R Ravi, Indrek Ratsep, Cristina Sampaio, Manmohan Singh, Petr Svoboda, Ian Roberts
Trials 2009, 10:109 (3 December 2009)

Response to: The BRAIN TRIAL: a randomised, placebo controlled tr ial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Vincent F Simmon
Trials 2009, 10:110 (3 December 2009)

Response to: The BRAIN TRIAL: a randomized, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury - authors' reply
Ian Roberts, Haleema Shakur
Trials 2009, 10:111 (3 December 2009)